Pfizer, Eyetech to collaborate on AMD, DME treatment

NEW YORK — Pfizer and Eyetech Pharmaceuticals will jointly develop and commercialize a drug for macular diseases, the companies announced yesterday.

The drug, Macugen (pegaptanib sodium), is an aptamer Eyetech has been developing as a potential treatment for age-related macular degeneration and diabetic macular edema.

Macugen has been granted fast-track status by the Food and Drug Administration for the treatment of the exudative form of age-related macular degeneration (AMD) as well as for diabetic macular edema, according to a news release issued by the companies.

Macugen selectively binds to and neutralizes vascular endothelial growth factor. It was shown in early clinical studies to inhibit abnormal blood vessel growth. Early trials also showed that the drug can stabilize or reverse blood vessel leakage in the back of the eye, resulting in improved vision in 26% of patients, according to the release.

Eyetech’s phase 3 study of the drug for wet AMD involves almost 1,200 patients in 117 sites worldwide. Macugen is being developed both as both a monotherapy and in combination with photodynamic therapy.

If the drug receives regulatory approval, Pfizer and Eyetech will comarket the drug in the United States, and Pfizer will retain exclusive marketing rights outside the United States.